CN114555813A - 治疗雷特综合征的胆固醇24-水解酶的表达载体 - Google Patents
治疗雷特综合征的胆固醇24-水解酶的表达载体 Download PDFInfo
- Publication number
- CN114555813A CN114555813A CN202080051431.4A CN202080051431A CN114555813A CN 114555813 A CN114555813 A CN 114555813A CN 202080051431 A CN202080051431 A CN 202080051431A CN 114555813 A CN114555813 A CN 114555813A
- Authority
- CN
- China
- Prior art keywords
- vector
- treatment
- rtt
- cholesterol
- rett syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13098—Cholesterol 24-hydroxylase (1.14.13.98)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175767.3 | 2019-05-21 | ||
| EP19175767 | 2019-05-21 | ||
| PCT/EP2020/064092 WO2020234363A2 (en) | 2019-05-21 | 2020-05-20 | Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114555813A true CN114555813A (zh) | 2022-05-27 |
Family
ID=66751865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080051431.4A Pending CN114555813A (zh) | 2019-05-21 | 2020-05-20 | 治疗雷特综合征的胆固醇24-水解酶的表达载体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220233654A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3972631B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7624410B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114555813A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020234363A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023205303A1 (en) * | 2022-04-20 | 2023-10-26 | The Regents Of The University Of California | Microglial cells as therapeutic targets in neurodevelopmental disorders |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009034127A1 (en) * | 2007-09-12 | 2009-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the cyp46a1 gene for the treatment of alzheimer's disease |
| US20140179770A1 (en) * | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN105682688A (zh) * | 2013-06-26 | 2016-06-15 | 雷特综合征研究信托 | Rett综合征及其治疗 |
| US20160175462A1 (en) * | 2013-06-17 | 2016-06-23 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
| US20180265927A1 (en) * | 2004-02-17 | 2018-09-20 | The Hospital For Sick Children | Mecp2e1 gene |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| ES2566495T3 (es) * | 2010-10-15 | 2016-04-13 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Vector de expresión para colesterol 24-hidrolasa en terapia de la enfermedad de Huntington |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| RU2017110868A (ru) * | 2014-09-25 | 2018-10-25 | Колд Спринг Харбор Лаборатори | Лечение синдрома ретта |
| AU2016366549B2 (en) | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| FI3574091T3 (fi) * | 2017-01-30 | 2023-05-03 | Brainvectis | Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa |
| EP3388520A1 (en) * | 2017-04-11 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof |
| EP3635122A4 (en) * | 2017-06-06 | 2021-03-31 | University of Massachusetts | SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME |
-
2020
- 2020-05-20 EP EP20726457.3A patent/EP3972631B1/en active Active
- 2020-05-20 CN CN202080051431.4A patent/CN114555813A/zh active Pending
- 2020-05-20 WO PCT/EP2020/064092 patent/WO2020234363A2/en not_active Ceased
- 2020-05-20 US US17/611,966 patent/US20220233654A1/en active Pending
- 2020-05-20 JP JP2021568858A patent/JP7624410B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180265927A1 (en) * | 2004-02-17 | 2018-09-20 | The Hospital For Sick Children | Mecp2e1 gene |
| WO2009034127A1 (en) * | 2007-09-12 | 2009-03-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the cyp46a1 gene for the treatment of alzheimer's disease |
| US20140179770A1 (en) * | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US20160175462A1 (en) * | 2013-06-17 | 2016-06-23 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
| CN105793425A (zh) * | 2013-06-17 | 2016-07-20 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| CN105682688A (zh) * | 2013-06-26 | 2016-06-15 | 雷特综合征研究信托 | Rett综合征及其治疗 |
Non-Patent Citations (3)
| Title |
|---|
| MARCO SEGATTO等: "Cholesterol Metabolism Is Altered in Rett Syndrome: A Study on Plasma and Primary Cultured Fibroblasts Derived from Patients", vol. 9, no. 8, pages 1 - 6 * |
| 冯荣芳等: "《老年性痴呆诊疗学》", vol. 1, 31 August 2010, 河北科学技术出版社, pages: 305 * |
| 郑观成: "《脑老化科学》", vol. 1, 31 October 2008, 上海复旦大学出版社, pages: 242 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3972631A2 (en) | 2022-03-30 |
| WO2020234363A3 (en) | 2021-11-18 |
| WO2020234363A2 (en) | 2020-11-26 |
| WO2020234363A8 (en) | 2021-10-07 |
| EP3972631C0 (en) | 2024-07-10 |
| CA3140809A1 (en) | 2020-11-26 |
| US20220233654A1 (en) | 2022-07-28 |
| JP7624410B2 (ja) | 2025-01-30 |
| JP2022534202A (ja) | 2022-07-28 |
| EP3972631B1 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020050660A (ja) | 脊髄疾患の遺伝子療法 | |
| AU2026200191A1 (en) | Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2 | |
| AU2025275257A1 (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| US20250090641A1 (en) | Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias | |
| HUE026796T2 (en) | Cholesterol 24-hydrolase expression vector for the treatment of huntington's disease | |
| JP7624410B2 (ja) | レット症候群の治療におけるコレステロール 24-ヒドロラーゼのための発現ベクター | |
| US20230183741A1 (en) | Disease correction by delivery of aav8 vectors expressing codon optimized naglu | |
| CA3140809C (en) | Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome | |
| US20230279422A1 (en) | Recombinant aav vectors for treating nervous system diseases | |
| HK40097390B (en) | Expression vector for cholesterol 24-hydrolase for the prevention of amyotrophic lateral sclerosis | |
| HK40097390A (en) | Expression vector for cholesterol 24-hydrolase for the prevention of amyotrophic lateral sclerosis | |
| HK40061073B (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| HK40061073A (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| HK40052708A (zh) | 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体 | |
| WO2024079317A1 (en) | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies | |
| WO2024197073A2 (en) | Aav-mediated gene therapy | |
| HK40052708B (en) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis | |
| Foust et al. | Gene Transfer in Spinal Muscular Atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |